Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2023-04-03 00:00:00 ET · period of report 2023-03-30 · accession 0001209191-23-022400 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $4.78 | +203.4K | 2.32M | +10% | +$972.9K |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Lian Brian | Pres, CEO, Dir | S - Sale+OE | $17.31 | -243.4K | 2.23M | -10% | -$4.21M |
| D | 2023-04-03 | 2023-04-03 | VKTX | Lian Brian | Pres, CEO, Dir | A - Grant | $0.00 | +300.0K | 2.53M | +13% | $0 |
| D | 2023-04-03 | 2023-04-03 | VKTX | Lian Brian | Pres, CEO, Dir | F - Tax | $17.57 | -200.0K | 2.33M | -8% | -$3.51M |
| DM | 2023-04-03 | 2023-03-30+ | VKTX | Lian Brian | Pres, CEO, Dir | M - OptEx | $0.00 | -203.4K | 134.1K | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2023-03-30 | M | A | 115,852 | $1.23 | 2,388,815 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2023-03-30 | M | A | 19,530 | $9.49 | 2,408,345 | D | — | — | |
| 3 | Common | Common Stock, par value $0.00001 per share | 2023-03-30 | S | D | 88,000 | $16.95 | 2,320,345 | D | — | — | |
| 4 | Common | Common Stock, par value $0.00001 per share | 2023-03-30 | S | D | 65,382 | $17.45 | 2,254,963 | D | — | — | |
| 5 | Common | Common Stock, par value $0.00001 per share | 2023-03-31 | M | A | 67,970 | $9.49 | 2,322,933 | D | — | — | |
| 6 | Common | Common Stock, par value $0.00001 per share | 2023-03-31 | S | D | 67,970 | $17.45 | 2,254,963 | D | — | — | |
| 7 | Common | Common Stock, par value $0.00001 per share | 2023-04-03 | S | D | 22,000 | $17.85 | 2,232,963 | D | — | — | |
| 8 | Common | Common Stock, par value $0.00001 per share | 2023-04-03 | A | A | 300,000 | $0.00 | 2,532,963 | D | — | — | (F2) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals. |
| 9 | Common | Common Stock, par value $0.00001 per share | 2023-04-03 | F | D | 200,000 | $17.57 | 2,332,963 | D | — | — | (F3) These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. |
| 10 | Derivative | Stock Option (Right to Buy) | 2023-03-31 | M | D | 67,970 | $0.00 | 0 | D | $9.49 · 2016-05-04 to 2025-05-04 | 67,970 Common Stock | (F5) 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. |
| 11 | Derivative | Stock Option (Right to Buy) | 2023-03-30 | M | D | 19,530 | $0.00 | 67,970 | D | $9.49 · 2016-05-04 to 2025-05-04 | 19,530 Common Stock | (F5) 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date. |
| 12 | Derivative | Stock Option (Right to Buy) | 2023-03-30 | M | D | 115,852 | $0.00 | 134,148 | D | $1.23 · 2018-01-05 to 2027-01-05 | 115,852 Common Stock | (F4) 25% of the shares subject to the option vested on each one year anniversary of the grant date. |